Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Q1 Results

RNS Number : 7843Y

Benchmark Holdings PLC

28 February 2025

 

28 February 2025

 

Information within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulations (EU) No. 596/2014

 

Benchmark Holdings plc

("Benchmark", the "Company" or the "Group")

 

Q1 Results

(Three months ended 31 December 2024)

 

Stepping stone quarter -

Progress towards completion of Genetics disposal

and transition towards streamlined organisation

 

In compliance with the terms of the Company's unsecured Green bond, which requires it to publish quarterly financial information, Benchmark, the aquaculture biotechnology business, announces its unaudited results for the three months ended 31 December 2024 (the "Period"), which constitute the first quarter for the fiscal year ("FY") 2025. All Q1 FY24 and Q1 FY25 figures quoted in this announcement are based on unaudited accounts.

 

Following the decision to sell the Genetics business in FY24, it has been classified as discontinued operations and the figures for Q1 FY24 have been restated. The figures shown for the continuing business exclude Genetics and include Group corporate costs previously allocated to Genetics.

Financial highlights (continuing business)

·    Q1 FY25 revenues from continuing operations were £17.7m, 30% below the prior year (-25% CER) resulting from:

o  Advanced Nutrition revenues of £16.1m, 16% below Q1 FY24 (-11% CER) reflecting continuing soft shrimp markets as well as a change in product mix compared to the prior year    

o  Health revenues of £1.6m reflect the restructured Health business area currently focused on Salmosan® Vet (Q1 FY24 revenues which included Ectosan® Vet and CleanTreat® were £6.1m)

·    Q1 FY25 Adjusted EBITDA from continuing operations was a loss of £0.2m (Q1 FY24: profit £3.5m) due to lower revenues and lower gross profit margin in Advanced Nutrition, partially offset by a reduction in operating costs

·    Operating costs for the continuing business were 15% below the prior year; they reflect the corporate costs for the whole Group including those previously allocated to Genetics, and before the planned streamlining to be conducted post completion of the Genetics disposal

·    Cash, liquidity and net debt:

o  Cash of £13.8m (30 September 2024: £23.1m) and liquidity (cash and available facility) of £21.1m (30 September 2024: £34.3m)

o  Net debt3 of £62.0m (30 September 2024: £49.0m)

Operational highlights

·    Advanced Nutrition - Focus on operational efficiency, product range expansion and innovation to mitigate soft markets  

o  Successful expansion of product portfolio through continuous innovation

§ Increasing adoption of recently launched products and technologies including SnappArt® and Snapp360®

§ Successful launch of a new shrimp diet specifically tailored to the Ecuadorian market  

o  Strong performance in the European marine fish sector driven by growing product portfolio and expansion into the nursery segment 

o  Steps taken to strengthen the high margin diets and health segments through the integration of the technical services and product management teams

o  2025 Great Salt Lakes Artemia harvest completed delivering high quality Artemia for the second year in a row; this will benefit future margins as the higher-grade product goes through inventory

·    Health - Progress towards the development of an alternative business model for Ectosan® Vet and CleanTreat®

o  Progress made towards the introduction of a new land-based configuration and business model for Ectosan® Vet and CleanTreat® through a new JV with Water AS; confirmed customer interest in the new capital-light solution

·    Group - Progress towards completion of Genetics disposal and return of capital announced in November 2024  

o  Regulatory clearances well advanced with completion expected by end of March 2025

o  Plans for delivery of transition services agreement are in place

o  Post completion of the Genetics disposal, the Company will make a separate announcement regarding use of proceeds and plans for the continuing business.

§ As previously announced proceeds will be used to return capital to shareholders and to reduce the Company's leverage, by repaying the Group's unsecured listed green bond and drawn amounts under the Group's revolving credit facility, thereby strengthening the balance sheet of the continuing business

 

Current trading and outlook - trading in line with management's expectations for the full year

The Group is trading in line with management's expectations for the full year underpinned by improving performance in Advanced Nutrition since the latter part of Q1 FY25. Health is now a profitable, cash positive business focusing on Salmosan® Vet. 

 

Financial Summary - continuing operations

£mQ1 FY25Q1 FY24
Restated
% AER% CER**FY24
(full year)
Revenue17.725.3-30%-25%90.4
Adjusted
Adjusted EBITDA1(0.2)3.5-107%-116%11.9
Adjusted Operating loss2(1.1)(2.1)46%29%(16.6)
Statutory
Operating loss(6.0)(5.6)-9%-15%(35.5)
Loss before tax(7.1)(9.1)22%18%(45.9)
Loss for the period(7.3)(8.5)14%10%(44.3)
Basic loss per share (p) (including discontinued operations)(1.34)(1.03)(5.34)
Net debt362.074.649.0
Business Area summary  
£mQ1 FY25Q1 FY24% AER% CER**FY24
(full year)
Revenue
Advanced Nutrition16.119.3-16%-11%75.9
Health1.66.1-73%-71%14.5
Adjusted EBITDA1
Advanced Nutrition0.84.6-82%-89%14.4
Health0.30.6-43%-41%2.1
*Constant exchange rate (CER) figures derived by retranslating current year figures using previous year's foreign exchange rates (1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation, amortisation, and impairment), before exceptional items (2) Adjusted operating loss is operating gain or loss before exceptional items and amortisation of intangible assets excluding development costs (3) Net debt is cash and cash equivalents less loans and borrowings    The Genetics business which is the subject of a disposal process has been treated as held for sale and discontinued.   Trond Williksen, CEO, commented:   "Q1 FY25 has been a stepping-stone quarter for us representing a period of transition for Benchmark ahead of completion of the Genetics disposal and streamlining of the continuing business. Our reported performance reflects ongoing weakness in the global shrimp markets for Advanced Nutrition coupled with a temporary change in product mix and a solid performance in Health.   "Looking forward we expect an improvement in trading conditions and margins, and we have two well positioned businesses capable of delivering attractive shareholder returns. Our restructured Health business performs well as a cash generative business and is advancing towards a relaunch of a new land-based business model for Ectosan® Vet and CleanTreat®."   Analyst / investor webcast at 08:00 am UK time (09:00 CET) today   Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a webcast today starting at 09:00 CET time (08:00 UK time).   To attend the live webcast and for the opportunity to ask questions, please register and join at the following link: https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20250228_5       Equity Development webcast for retail investors at 12:00pm UK time today   Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial Officer will host a second webcast for retail investors and wealth managers at 12.00pm UK time today. The webcast is open to all existing and potential shareholders.   To register please visit: https://www.equitydevelopment.co.uk/news-and-events/benchmark-q1-investor-presentation-28february2025   Enquiries  
For further information, please contact:
Benchmark Holdings plcbenchmark@mphc.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Deutsche Numis (Broker and NOMAD)Tel: 020 7260 1000
Freddie Barnfield, Duncan Monteith, Sher Shah
MHP CommunicationsTel: +44(0)7884 494112
Katie Hunt, Reg Hoare                                                                                              benchmark@mhpgroup.com                  About Benchmark  Benchmark is a market leading aquaculture biotechnology company. Benchmark's mission is to drive sustainability in aquaculture by delivering products and solutions in advanced nutrition and health which improve yield, growth and animal health and welfare. Find out more at www.benchmarkplc.com. Management Report   As a result of the Genetics disposal and with the Genetics operations being classified as discontinued, these results are for the continuing operations (Advanced Nutrition and Health) albeit they continue to reflect the ongoing costs for the whole Group prior to completion of the Genetics disposal, after which the planned streamlining of the Group will be conducted.   Q1 Results for the Continuing Operations   Q1 FY25 has been a stepping stone quarter for Benchmark ahead of completion of the Genetics disposal and streamlining of the continuing business.   Benchmark's Q1 FY25 results reflect continued softness in the shrimp markets and the negative impact on margins from a change in product mix in Advanced Nutrition. Health performed well in the quarter, albeit below the prior year which included sales of Ectosan® Vet and CleanTreat®. As a result, Group revenues of £17.7m were 30% below the prior year (-25% CER), and the gross profit margin for the Group was 43% (Q1 FY24: 50%).   The Group has maintained strict financial discipline, and as a result operating costs were £7.3m, 15% below the prior year (13% at CER). R&D costs were marginally below the prior year at £0.6m (Q1 FY24: £0.7m).  There has been no capitalised R&D incurred during the quarter.   Adjusted EBITDA was a loss of £0.2m in the period (Q1 FY24: profit of £3.5m) as a result of lower revenues and gross margin partially offset by lower operating costs. High logistics costs incurred in FY 2024 in Advanced Nutrition continued in the period due in part to necessary re-routing driven by geopolitical conflicts.   Depreciation and amortisation reduced significantly from the comparative period last year to £4.2m (Q1 FY24: £9.0m). The reduction was driven by lower depreciation in Health due to the decommissioning of the CleanTreat® units in the prior year. Exceptional costs incurred in the period of £1.6m (Q1 FY24: £0.1m) related to costs associated with the strategic review.   Net finance cost in the period was £1.0m; (Q1 FY24: £3.5m) with the reduction primarily explained by net forex exchange gains in the period of £1.4m compared to a loss in the prior year (Q1 FY24: £1.3m loss).   The Group reported a loss before tax from continuing operations of £7.1m (Q1 FY24: £9.1m loss) and the loss after tax for the period including discontinued operations was £10.2m (Q1 FY24: loss £7.6m).   Net cash outflow from operating activities for the period (including discontinued operations) was £8.1m (Q1 FY24: £5.6m outflow) reflecting the lower revenue.  The increased outflow is due to the higher cash loss reported for the quarter after a lower depreciation charge as noted above, partially offset by a lower outflow in working capital in the quarter.   Net cash used in investing activities was £0.7m (Q1 FY24: £0.8m) of which capex was £0.9m (Q1 FY24: £1.0m).  Net cash outflow from financing activities was £0.8m with interest and lease payments being offset by a drawing of £4.0m on the RCF.  All this left a net decrease in cash in the quarter of £9.6m (Q1 FY24: £11.8m outflow) and a cash position of £13.8m at the end of the quarter.   Advanced Nutrition   As predicted Advanced Nutrition had a soft start to the new financial year in Q1 FY25. Revenues were £16.1m, 16% below the prior year (-11% CER). By geography, performance was strong in Europe driven by sales to the marine fish market where we are successfully expanding into the nursery segment, and in the Americas, while Asia was most affected by soft conditions in the shrimp markets.     By product area Artemia revenues were 19% below the prior year due to a change in available Artemia grades. Artemia is a natural resource with fluctuation in hatching rate (the key quality parameter), and during the period we  had a greater influx of inventory of Artemia with lower hatching rates. In addition, demand for Diets and Health products has been lower reflecting increased price sensitivity from customers due to the soft shrimp markets and as a result revenues from Diets and Health products were down 11% and 25% respectively compared to Q1 FY24.     Innovation continues to be a very important element of the strategy in Advanced Nutrition. We continued the successful roll-out of recently launched technologies including Snapp Art® and Snapp 360®, and our newly launched diet tailored to the Ecuadorian market was sold out in its first period of sales.   The gross margin in Advanced Nutrition was also impacted by the product mix including lower sales of Health and Diets products and lower Artemia grades resulting from historic harvests. As a result, gross margin in the quarter was down at 41% (Q1 FY24: 53%). Logistics costs remained high in the period due to ongoing disruption to trading routes, but this was mostly offset by ongoing efforts to reduce costs and improve efficiency.  Overall, operating costs were marginally above last year at £5.2m (Q1 FY24: £5.0m).  Adjusted EBITDA was £0.8m (Q1 FY24: £4.6m) driven by the lower sales and margins mentioned above.   The latter part of the quarter saw an improvement in sales and margins which has continued post period end, and we expect this to carry on as the year progresses. The strategy in place and the steps we have taken over the last 18 months to mitigate the impact of soft shrimp markets have placed Advanced Nutrition in a strong position for market recovery and for its longer-term future.   Health   Revenues in Q1 FY25 were £1.6m (Q1 FY24: £6.1m) primarily reflecting the pause in sales of Ectosan®Vet and CleanTreat® while a new business model for the offering is developed. Sales of Salmosan®Vet of £1.6m (Q1 FY24: £2.1m) were driven by sales in Norway and Chile which experienced high sea lice levels, offset primarily by lower sales in the Faroe Islands compared to last year. Operating costs were significantly below the prior year at £0.7m (Q1 FY24: £1.9m) as a result of the restructuring conducted in FY24.  Adjusted EBITDA was £0.3m in the quarter (Q1 FY24: £0.6m).   An important development in the period is the progress made towards a new land-based configuration and business model for Ectosan® Vet and CleanTreat®. We are working in partnership with a specialist solutions provider, Water AS, and have significant expression of interest from potential customers who have previously used Ectosan® Vet and CleanTreat® and who remain interested in incorporating the solution into their sea lice toolkit with a simplified infrastructure and cost-efficient business model.       Update on the disposal of the Genetics business   Progress towards the completion of the sale of the Genetics business is well advanced. The Company has obtained most of the regulatory clearances, and the Company has well-developed plans in place to deliver on the transaction services agreement. Post completion, the Company will announce its plans for use of proceeds as well as plans for the remaining business. As previously announced, proceeds will be used to return capital to shareholders and to reduce the Company's leverage by repaying the Group's unsecured listed green bond and drawn amounts under the Group's revolving credit facility   Current Trading and Outlook   The Group is trading in line with management's expectations for the full year underpinned by improving performance in the latter part of Q1 and into Q2 in Advanced Nutrition and continuing good performance in Health. Consolidated Income Statement for the period ended 31 December 2024  
All figures in £000'sNotesQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Revenue417,72225,31390,365
Cost of sales(10,146)(12,563)(46,418)
Gross profit7,57612,75043,947
Research and development costs(567)(687)(2,443)
Other operating costs(7,257)(8,568)(29,582)
Adjusted EBITDA²(248)3,49511,922
Exceptional - restructuring, acquisition and disposal related items5(1,574)(94)(5,581)
EBITDA¹(1,822)3,4016,341
Depreciation and impairment(840)(5,093)(10,949)
Amortisation and impairment(3,381)(3,864)(30,891)
Operating loss(6,043)(5,556)(35,499)
Finance cost6(5,349)(4,938)(14,209)
Finance income64,3251,4053,783
Loss before taxation(7,067)(9,089)(45,925)
Tax on loss7(213)6211,646
Loss from continuing operations(7,280)(8,468)(44,279)
Discontinued operations
Profit/(loss) from discontinued operations, net of tax8(2,919)8445,159
(10,199)(7,624)(39,120)
(Loss)/profit for the year attributable to:
-Owners of the parent(9,927)(7,627)(39,464)
- Non-controlling interest(272)3344
(10,199)(7,624)(39,120)
Earnings per share
Basic loss per share (pence)9(1.34)(1.03)(5.34)
Diluted loss per share (pence)9(1.34)(1.03)(5.34)
Earnings per share - continuing operations
Basic loss per share (pence)9(0.98)(1.14)(5.99)
Diluted loss per share (pence)9(0.98)(1.14)(5.99)
Adjusted EBITDA from continuing operations(248)3,49511,922
Adjusted EBITDA from discontinued operations86193,17916,698
Total Adjusted EBITDA3716,67428,620
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and impairment 2 Adjusted EBITDA - EBITDA before exceptional items including acquisition related items * Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   The accompanying notes are an integral part of this consolidated financial information.   Consolidated Statement of Comprehensive Income for the period ended 31 December 2024  
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Loss for the period(10,199)(7,624)(39,120)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences10,689(7,413)(20,528)
Cash flow hedges - changes in fair value(93)(890)(3,505)
Cash flow hedges - reclassified to profit or loss2691202,687
Other comprehensive income for the period10,865(8,183)(21,346)
Total comprehensive income for the period666(15,807)(60,466)
Total comprehensive income for the period attributable to:
- Owners of the parent974(15,741)(60,259)
- Non-controlling interest(308)(66)(207)
666(15,807)(60,466)
Total comprehensive income for the period attributable to owners of the parent:
- Continuing operations(194)(12,810)(54,122)
- Discontinued operations**1,168(2,931)(6,137)
974(15,741)(60,259)
* Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8). **Total comprehensive income for the period relating to discontinued operations for the quarter includes the loss of £2.9m (Q1 2024: profit £0.8m; FY 2024: £5.2m) and foreign exchange gain of £4.1m (Q1 2024: loss £3.8m; FY 2024 loss £11.3m).   The accompanying notes are an integral part of this consolidated financial information Consolidated Balance Sheet as at 31 December 2024

31 December 2024

31 December 2023
30 September 2024
All figures in £000'sNotes(audited)(audited)(audited)
Assets
Property, plant and equipment10,54771,66410,107
Right-of-use assets3,48016,5134,052
Intangible assets120,154194,953115,527
Equity-accounted investees2,5053,7802,315
Other investments-1-
Biological and agricultural assets-23,779-
Non-current assets136,686310,690132,001
Inventories23,94824,50523,674
Biological and agricultural assets-19,926-
Corporation tax asset417-347
Trade and other receivables41,44056,38142,539
Cash and cash equivalents13,80824,16423,088
79,613124,97689,648
Assets held for sale10164,468500163,252
Current assets244,081125,476252,900
Total assets380,767436,166384,901
Liabilities
Trade and other payables(22,588)(33,513)(30,102)
Loans and borrowings11(73,442)(18,682)(69,233)
Corporation tax liability(1,087)(5,929)-
Provisions(204)(2,410)(233)
(97,321)(60,534)(99,568)
Liabilities directly associated with the assets held for sale10(44,180)-(46,697)
Current liabilities(141,501)(60,534)(146,265)
Loans and borrowings11(2,401)(80,032)(2,837)
Other payables(1,670)(5,930)(1,607)
Deferred tax(9,758)(22,168)(9,923)
Provisions-(440)-
Non-current liabilities(13,829)(108,570)(14,367)
Total liabilities(155,330)(169,104)(160,632)
Net assets225,437267,062224,269
Issued capital and reserves attributable to owners of the parent
Share capital12740739740
Additional paid-in share capital1237,49037,42837,490
Capital redemption reserve555
Retained earnings136,655176,114146,080
Hedging reserve(845)(973)(1,021)
Foreign exchange reserve45,69547,60334,970
Equity attributable to owners of the parent219,740260,916218,264
Non-controlling interest5,6976,1466,005
Total equity and reserves225,437267,062224,269
  The accompanying notes are an integral part of this consolidated financial information Consolidated Statement of Changes in Equity for the period ended 31 December 2024    
All figures in £000'sShare
capital
Additional paid-in share capitalOther
reserves*
Hedging
reserve
Retained
earnings
Total attributable
to equity holders of
parent
Non-
controlling
interest
Total
equity
As at 1 October 2024 (audited)74037,49034,975(1,021)146,080218,2646,005224,269
Comprehensive income/(loss) for the period
Loss for the year----(9,927)(9,927)(272)(10,199)
Other comprehensive income--10,725176-10,901(36)10,865
Total comprehensive income for the year--10,725176(9,927)974(308)666
Contributions by and distributions to owners
Share-based payment----502502-502
Total contributions by and distributions to owners----502502-502
Total transactions with owners of the Company----502502-502
As at 31 December 2024 (unaudited)74037,49045,700(845)136,655219,7405,697225,437
As at 1 October 2023 (audited)73937,42854,952(203)183,489276,4056,212282,617
Comprehensive income/(loss)for the period
(Loss)/profit for the period----(7,627)(7,627)3(7,624)
Other comprehensive income/(loss)--(7,344)(770)-(8,114)(69)(8,183)
Total comprehensive income/(loss)for the period--(7,344)(770)(7,627)(15,741)(66)(15,807)
Contributions by and distributions to owners
Share-based payment----252252-252
Total contributions by and distributions to owners----252252-252
Total transactions with owners of the Company----252252-252
As at 31 December 2023 (unaudited)73937,42847,608(973)176,114260,9166,146267,062
As at 1 October 2023 (audited)73937,42854,952(203)183,489276,4056,212282,617
Comprehensive income for the period
(Loss)/profit for theyear----(39,464)(39,464)344(39,120)
Other comprehensive income--(19,977)(818)-(20,795)(551)(21,346)
Total comprehensive income for the year--(19,977)(818)(39,464)(60,259)(207)(60,466)
Contributions by and distributions to owners
Share issue162---63-63
Share-based payment----2,0552,055-2,055
Total contributions by and distributions to owners162--2,0552,118-2,118
Total transactions with owners of the Company162--2,0552,118-2,118
As at 30 September 2024 (audited)74037,49034,975(1,021)146,080218,2646,005224,269
*Other reserves in this statement is an aggregation of capital redemption reserve and foreign exchange reserve   The accompanying notes are an integral part of this consolidated financial information. Consolidated Statement of Cash Flows for the period ended 31 December 2024  
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024
(audited)
Cash flows from operating activities
Loss for the period(10,199)(7,624)(39,120)
Adjustments for:
Depreciation and impairment of property, plant and equipment2,2012,9699,319
Depreciation and impairment of right-of-use assets3643,2807,001
Amortisation and impairment of intangible fixed assets3,3814,26832,529
(Profit)/loss on sale of property, plant and equipment(77)5(416)
Finance income(106)(210)(430)
Finance costs2,8062,68511,293
Profit on disposal of investments in joint ventures-(42)(42)
Share of loss/(profit) of equity-accounted investees, net of tax260(318)(1,288)
Foreign exchange loss2007451,179
Share-based payment expense5022522,054
Tax expense252433495
Decrease/(increase) in trade and other receivables4,9571,191(1,136)
Decrease in inventories11757089
(Increase)/decrease in biological and agricultural assets(2,847)813(718)
Decrease in trade and other payables(9,120)(13,393)(9,974)
(Decrease)/increase in provisions(29)7(2,012)
(7,338)(4,369)8,823
Income taxes paid(782)(1,204)(6,819)
Net cash flows generated from/(used by) operating activities(8,120)(5,573)2,004
Investing activities
Purchase of investments in associates--(209)
Receipts from disposal of subsidiaries, joint ventures, and other investments-3737
Purchases of property, plant and equipment(819)(921)(3,509)
Proceeds from sales of intangible assets--32
Purchase of intangibles(68)(50)(268)
Capitalised research and development costs-(62)(149)
Proceeds from sale of fixed assets10718804
Interest received106204430
Net cash flows used in investing activities(674)(774)(2,832)
Financing activities
Proceeds from exercise of share options--63
Proceeds from bank or other borrowings, net of borrowing fees4,000-8,196
Repayment of bank or other borrowings(506)(386)(1,990)
Interest and finance charges paid(2,155)(2,250)(9,119)
Repayments of lease liabilities(2,162)(2,854)(8,121)
Net cash used in financing activities(823)(5,490)(10,971)
Net decrease in cash and cash equivalents(9,617)(11,837)(11,799)
Cash and cash equivalents at beginning of period23,08836,52536,525
Effect of movements in exchange rate337(524)(1,638)
Cash and cash equivalents at end of period13,80824,16423,088
   The accompanying notes are an integral part of this consolidated financial information. Unaudited notes to the quarterly financial statements for the period ended 31 December 2024 1.       Basis of preparation Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled in the United Kingdom. These consolidated quarterly financial statements as at and for the three months ended 31 December 2024 comprises those of the Company and its subsidiaries (together referred to as the 'Group'). These consolidated quarterly financial statements do not comprise statutory accounts within the meaning of section 434 of the Companies Act 2006 and are unaudited. These financial statements do not include all the information required for a complete set of IFRS financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance since the last annual financial statements. The Group's last annual statutory financial statements as at and for the year ended 30 September 2024 were prepared in accordance with (i) UK-adopted International Accounting Standards and (ii) IFRS adopted pursuant to Regulation (EC) No. 1606/2002 as it applied in the European Union ("Adopted IFRS") and are available from the Company's website at www.benchmarkplc.com. The prior year comparatives are derived from audited financial information for Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for the year ended 30 September 2024 and the unaudited financial information in the Quarterly Financial Report for the three months ended 31 December 2023. The comparative figures for the financial year ended 30 September 2024 are not the Company's statutory accounts for that financial year. Those accounts were approved by the Directors on 12 December 2024 and have been delivered to the Registrar of Companies. The audit report received on those accounts was (i) unqualified and (ii) did not contain a statement under section 498(2) or (3) of the Companies Act 2006 but did contain an emphasis of matter paragraph in relation to going concern.   Statement of Compliance These consolidated quarterly financial statements have been prepared and approved by the Directors in accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These financial statements do not include all of the information required for the full annual financial statements and should be read in conjunction with the Group's last annual consolidated financial statements as at and for the year ended 30 September 2024. These consolidated quarterly financial statements were approved by the Board of Directors on 28 February 2025.   Going concern As at 31 December 2024 the Group had net assets of £225.4m (30 September 2024: £224.3m), including cash of £13.8m (30 September 2024: £23.1m) as set out in the consolidated balance sheet. The Group made a total loss for the three-month period of £10.2m (year ended 30 September 2024: loss £39.1m).   The Directors have reviewed forecasts and cash flow projections for a period of at least 12 months including downside sensitivity assumptions in relation to trading performance across the Group to assess the impact on the Group's trading and cash flow forecasts and on the forecast compliance with the covenants included within the Group's financing arrangements.   In the downside analysis performed, the Directors considered severe but plausible scenarios on the Group's trading and cash flow forecasts. Key downside sensitivities modelled included assumptions on lower sales growth from a possible slower recovery in the shrimp market in Advanced Nutrition and have not included any sales from relaunching Ectosan®/CleanTreat® sales within Health. The recent restructuring of the Health business area which currently focuses on the Salmosan business has derisked the cash utilisation improving the likelihood of cash generation within that business area for the foreseeable future, and Ectosan®/CleanTreat® sales will only be relaunched with customer investment to mitigate the Group's cashflow exposure. Additional downside sensitivities have been identified and modelled within the discontinued Genetics business for slower commercialisation of SPR shrimp, slower salmon egg sales growth in Chile and removal of an additional financing opportunity. Further mitigating measures within the control of management have been identified should they be required in response to any or all of these sensitivities, including reductions in areas of discretionary spend, tight control over new hires, deferral of capital projects and temporary hold on R&D for non-imminent products.   In the prior year on 26 March 2024, an additional facility of £7.5m was added to the existing RCF with an expiry date of 31 March 2025. The original £20m RCF term remained unaltered, ending on 27 June 2025.  The term of the additional facility of £7.5m was subsequently extended on 20 December 2024 to expire on 27 June 2025 matching the expiry of the original RCF.  Furthermore, the Group's unsecured NOK 750m bond is due to expire in the current financial year in September 2025.   On 25 November, an agreement was signed to sell the whole Genetics business for consideration of up to £260m on a debt-free cash-free basis, with £230m received up front and up to £30m earnout receivable in three years. Completion of the sale is subject to anti-trust clearances which are expected to be received within the next few weeks with most clearances having now been received. The funds received upon completion will allow all finance facilities to be repaid whilst ensuring that adequate operational liquidity is available for the continuing businesses for the forecast period. In the absence of completion of the deal, the forecast would require continuing finance facilities to be available to the Group. The Directors are confident that the existing facilities due to expire this year could be renewed or replaced before expiry with the trading platform showing resilience to market conditions and other challenges presented during the last year and relationships with finance providers strong.   1.      Basis of preparation (continued)   Based on their assessment, the Directors believe it remains appropriate to prepare the financial statements on a going concern basis. However, while the Directors remain confident that either the deal to sell the Genetics business will proceed as planned, or that the current facilities will be renewed or replaced this financial year before expiry, the requirement for either one of these events to take place represents a material uncertainty that may cast significant doubt on the Group's and Company's ability to continue as a going concern and therefore to continue realising their assets and discharging their liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate.   2.      Accounting policies   The accounting policies adopted are consistent with those used in preparing the consolidated financial statements for the financial year ended 30 September 2024.   Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total earnings. Alternative performance measures ('APMs') The Directors measure the performance of the Group based on a range of financial measures, including measures not recognised by UK or EU-adopted IFRS. These APMs may not be directly comparable with other companies' APMs, and the Directors do not intend these as a substitute for, or superior to, IFRS measures. Directors have presented the performance measures Adjusted EBITDA, Adjusted Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding fair value movement on biological assets because they monitor performance at a consolidated level using these and believe that these measures are relevant to an understanding of the Group's financial performance (see note 13). Furthermore, the Directors also refer to current period results using constant currency, which are derived by retranslating current period results using the prior year's foreign exchange rates. Use of estimates and judgements The preparation of quarterly financial information requires management to make certain judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual amounts may differ from these estimates.   In preparing these quarterly financial statements the significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended 30 September 2024.   3.      Segment information   Operating segments are reported in a manner consistent with the reports made to the chief operating decision maker. It is considered that the role of chief operating decision maker is performed by the Board of Directors.   The Group operates globally and for management purposes is organised into reportable segments based on the following business areas:   ·      Advanced Nutrition - manufactures and provides technically advanced nutrition and health products to the global aquaculture industry. ·      Health - the segment provides health products and services to the global aquaculture market. ·      Genetics - harnesses industry leading salmon breeding technologies combined with state-of-the-art production facilities to provide a range of year-round high genetic merit ova. Following management's decision and subsequent commitment to sell the Group's Genetics business, this has been classified as discontinued operations in the income statement and the figures for Q1 2024 have been restated.   In order to reconcile the segmental analysis to the consolidated income statement, corporate and inter-segment sales are also shown. Corporate sales represent revenues earned from recharging certain central costs to the operating business areas, together with unallocated central costs. Measurement of operating segment profit or loss Inter-segment sales are priced along the same lines as sales to external customers, with an appropriate discount being applied to encourage use of Group resources at a rate acceptable to local tax authorities.  This policy was applied consistently throughout the current and prior period. 3.     Segment information (continued)   Reconciliations of segmental information to IFRS measures  
Segmental Revenue
All figures in £000'sNotesQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024
(audited)
Genetics11,06215,16457,385
Advanced Nutrition16,11519,28375,918
Health1,6436,05914,525
Corporate1,3291,3494,040
Inter-segment sales(1,367)(1,382)(4,142)
Total28,78240,473147,726
Discontinued operations8(11,060)(15,160)(57,361)
Continuing operations17,72225,31390,365
 
Segmental Adjusted EBITDA
All figures in £000'sNotesQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024
(audited)
Genetics(102)2,49814,828
Advanced Nutrition8364,60014,373
Health3265702,055
Corporate(689)(994)(2,636)
Total3716,67428,620
Discontinued operations8(619)(3,179)(16,698)
Continuing operations(248)3,49511,922
 
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before taxation
All figures in £000'sNotesQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024
(audited)
Total reportable segment Adjusted EBITDA1,0607,66831,256
Corporate Adjusted EBITDA(689)(994)(2,636)
Adjusted EBITDA3716,67428,620
Exceptional - restructuring, acquisition and disposal related items(1,599)(517)(7,381)
Depreciation and impairment(2,565)(6,249)(16,320)
Amortisation and impairment(3,381)(4,268)(32,529)
Net finance costs(2,773)(2,831)(11,015)
Total loss before taxation(9,947)(7,191)(38,625)
Discontinued operations82,880(1,898)(7,300)
Continuing operations(7,067)(9,089)(45,925)
  4.     Revenue   The Group's operations and main revenue streams are those described in its financial statements to 30 September 2024. The Group's revenue is derived from contracts with customers.   Disaggregation of revenue In the following tables, revenue is disaggregated by primary geographical market and by sales of goods and services. The table includes a reconciliation of the disaggregated revenue with the Group's reportable segments (see note 3). Discontinued operations relate to Genetics following the decision to sell the division.   Sale of goods and provision of services
3 months ended 31 December 2024 (unaudited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Sale of goods10,41816,0741,643--28,13510,41817,717
Provision of services6425---6476425
Inter-segment sales236-1,329(1,367)---
11,06216,1151,6431,329(1,367)28,78211,06017,722
 
3 months ended 31 December 2023 (unaudited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Sale of goods14,84119,2544,459--38,55414,84123,713
Provision of services319-1,600--1,9193191,600
Inter-segment sales429-1,349(1,382)---
15,16419,2836,0591,349(1,382)40,47315,16025,313
 
12 months ended 30 September 2024 (audited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Sale of goods55,13175,80611,703--142,64055,13187,509
Provision of services2,230342,822--5,0862,2302,856
Inter-segment sales2478-4,040(4,142)---
57,38575,91814,5254,040(4,142)147,72657,36190,365
   4.     Revenue (continued)   Primary geographical markets  
3 months ended 31 December 2024 (unaudited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Norway4,387151934--5,4724,3871,085
Greece-2,359---2,359-2,359
Turkey272,146---2,173272,146
India-1,917---1,917-1,917
Faroe Islands1,583-99--1,6821,58399
United Kingdom1,628126--1,6551,62827
Ecuador-1,445---1,445-1,445
Chile845-526--1,371845526
Iceland1,137----1,1371,137-
Vietnam27737---76427737
Indonesia80786---86680786
Canada83-58--1418358
China155237---392155237
Rest of Europe5791,668---2,2475791,668
Rest of World5294,632---5,1615294,632
Inter-segment sales236-1,329(1,367)---
11,06216,1151,6431,329(1,367)28,78211,06017,722
3 months ended 31 December 2023 (unaudited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Norway9,5573114,809--14,6779,5575,120
Greece-1,948---1,948-1,948
Turkey91,898---1,90791,898
India-4,163---4,163-4,163
Faroe Islands1,472-432--1,9041,472432
United Kingdom774753--83477460
Ecuador321,489---1,521321,489
Chile984-623--1,607984623
Iceland1,233----1,2331,233-
Vietnam-1,635---1,635-1,635
Indonesia921,282---1,374921,282
Canada6022142--22460164
China98502---60098502
Rest of Europe3821,656---2,0383821,656
Rest of World4674,341---4,8084674,341
Inter-segment sales429-1,349(1,382)---
15,16419,2836,0591,349(1,382)40,47315,16025,313
  4.      Revenue (continued)   Primary geographical markets (continued)  
12 months ended 30 September 2024 (audited)
All figures in £000'sGeneticsAdvanced NutritionHealthCorporateInter-segment salesTotalDiscontinuedContinuing
Norway31,8031,0588,742--41,60331,8039,800
Greece-6,642---6,642-6,642
Turkey1077,197---7,3041077,197
India59,286---9,29159,286
Faroe Islands5,282-1,027--6,3095,2821,027
United Kingdom3,43659316--3,8113,436375
Ecuador406,203---6,243406,203
Chile3,678-1,499--5,1773,6781,499
Iceland7,118-113--7,2317,118113
Vietnam1410,536---10,5501410,536
Indonesia3914,993---5,3843914,993
Canada1,553692,828--4,4501,5532,897
China6103,156---3,7666103,156
Rest of Europe1,5955,108---6,7031,5955,108
Rest of World1,72921,533---23,2621,72921,533
Inter-segment sales2478-4,040(4,142)---
57,38575,91814,5254,040(4,142)147,72657,36190,365
  5.     Exceptional items within continuing operations - restructuring, acquisition and disposal related items   Items that are material because of their size or nature, are non-recurring and whose significance is sufficient to warrant separate disclosure and identification within the consolidated financial statements are referred to as exceptional items. The separate reporting of exceptional items helps to provide an understanding of the Group's underlying performance.
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Acquisition related items--158
Exceptional restructuring costs1,574945,682
Disposal related items--(259)
Total exceptional items1,574945,581
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   Exceptional restructuring costs for the quarter include £1.6m (Q1 2024: £0.1m; FY 2024: £4.5m) relating to the formal review of the Company's strategic options as announced in January 2024. Further exceptional restructuring costs were incurred in FY 2024 of £1.2m relating to redundancies and dilapidations provisions arising from restructuring Health, Nutrition and Corporate business areas.   Disposal related items in FY 2024 relate to income from asset disposals from Health businesses discontinued in earlier years offset by some small costs incurred.  Acquisition related items in FY 2024 relate to fees incurred on an aborted acquisition. 6.     Net finance costs from continuing operations
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Interest received on bank deposits181644
Foreign exchange gains on operating activities4,3071,3893,739
Finance income4,3251,4053,783
Lease interest(56)(195)(518)
Cash flow hedges - ineffective portion of changes in fair value(112)-(243)
Foreign exchange losses on operating activities(2,927)(2,701)(4,954)
Amortisation of capitalised borrowing fees(273)(210)(967)
Interest expense on financial liabilities measured at amortised cost(1,981)(1,832)(7,527)
Finance costs(5,349)(4,938)(14,209)
Net finance costs recognised in profit or loss(1,024)(3,533)(10,426)
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   7.     Taxation
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period1,0752311,948
Adjustment in respect of prior periods--(339)
Total current tax charge on continuing activities1,0752311,609
Deferred tax:
Origination and reversal of temporary differences(862)(852)(3,255)
Total deferred tax credit on continuing activities(862)(852)(3,255)
Total tax charge/(credit) on continuing activities213(621)(1,646)
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   The above excludes a tax expense in Q1 2025 of £0.0m (Q1 2024: £1.1m; FY 2024 £2.1m) from discontinued operations, this has been included in loss from discontinued operations, net of tax (note 8).   8.     Discontinued activities   The strategic review announced in January 2024 was completed in the quarter on 25 November 2024, with a Company announcement that it had entered into a binding agreement to sell its Genetics business area by way of the disposal of Benchmark Genetics Limited and Benchmark Genetics Norway AS and their respective subsidiaries to Starfish Bidco AS, a wholly owned subsidiary of Novo Holdings A/S.  The agreed deal includes initial consideration of £230m, on a debt-free cash-free basis, receivable on completion and additional contingent consideration of up to £30m receivable in three years' time based on trading performance of the core salmon subsegment in the period from 1 October 2024 to 30 September 2027.  The deal is subject to customary regulatory clearances and with most of these now received, completion is expected in the next few weeks.  At 30 September 2024, the Genetics business was treated as discontinued operations and the assets and liabilities transferred into held for sale as the sale at the year-end was considered highly probable, and this treatment continues (see note 10). Included within liabilities held for sale is £18.6m of borrowings held within Genetics.  The debt-free cash-free terms of the agreed deal prescribe that these facilities will be paid out of the proceeds received at completion.   Summary of restatement of Q1 FY24 results as reported in Q1 FY25 financial statements
Continuing operationsDiscontinued operations
All figures in £000'sRevenueAdjusted EBITDALoss from continuing operationsProfit from discontinued operations
As stated in Q1 FY24 financial statements40,4736,674(7,624)-
Reclassified Q1(15,160)(3,179)(844)844
Restated Q1 2025 financial statements25,3133,495(8,468)844
 
Results from discontinued operations
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Revenue11,06015,16057,361
Cost of sales(7,373)(9,547)(30,931)
Gross profit3,6875,61326,430
Research and development costs(871)(830)(3,276)
Other operating costs(1,937)(1,922)(7,744)
Share of profit of equity-accounted investees, net of tax(260)3181,288
Adjusted EBITDA6193,17916,698
Exceptional - restructuring, acquisition and disposal related items(25)(423)(1,800)
EBITDA5942,75614,898
Depreciation and impairment(1,725)(1,156)(5,371)
Amortisation and impairment-(404)(1,638)
Operating loss / Loss before taxation(1,131)1,1967,889
Net finance costs(1,749)702(589)
Loss before taxation(2,880)1,8987,300
Tax on loss(39)(1,054)(2,141)
Loss from discontinued operations(2,919)8445,159
*While all of the discontinued operations relate to the entire Genetics business area, the results above exclude intercompany transactions with the rest of the Benchmark group which are included within the Genetics segment in note 3, but which are eliminated within continuing activities.  These total £0.7m in the quarter (Q1 2024: £0.7m, FY 2024: £1.9m).   8.     Discontinued activities (continued)
Exceptional items within discontinued operations
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Restructuring costs25423965
Other--835
Total exceptional recognised254231,800
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   Exceptional costs included in discontinued operations in Genetics in the quarter arose from restructuring costs in relation to the shrimp genetics operations (Q1 FY24: £0.4m, FY24: £0.5m).  Other exceptional restructuring costs in FY 2024 include costs following the closure of the tilapia operations of £0.4m.  Additionally, other exceptional costs of £0.8m were incurred in FY 2024 in the uninsured culling of broodstock and clean-up costs after two separate isolated ISA incidents.   Results from discontinued operations by segment The results from discontinued operations relate solely to the Genetics operating segment.   9.     Loss per share   Basic loss per share is calculated by dividing the loss attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares in issue during the period.
Q1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Loss attributable to equity holders of the parent (£000)
Continuing operations(7,280)(8,468)(44,279)
Discontinued operations(2,647)8414,815
Total(9,927)(7,627)(39,464)
Weighted average number of shares in issue (thousands)740,338739,352739,575
Basic loss per share (pence)
Continuing operations(0.98)(1.14)(5.99)
Discontinued operations(0.36)0.110.65
Total(1.34)(1.03)(5.34)
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares outstanding to assume conversion of all dilutive potential ordinary shares. This is done by calculating the number of shares that could have been acquired at fair value (determined as the average market price of the Company's shares for the period) based on the monetary value of the subscription rights attached to outstanding share options and warrants. The number of shares calculated above is compared with the number of shares that would have been issued assuming the exercise of the share options and warrants.   Therefore, the Company is required to adjust the earnings per share calculation in relation to the share options that are in issue under the Company's share-based incentive schemes, and outstanding warrants. However, as any potential ordinary shares would be anti-dilutive due to losses being made there is no difference between basic loss per share and diluted loss per share for any of the periods being reported.   A total of 11,916,804 potential ordinary shares have not been included within the calculation of statutory diluted loss per share for the quarter end (30 September 2024: 13,656,055). These potential ordinary shares could dilute earnings/loss per share in the future.   10.   Assets held for sale   The strategic review announced in January 2024 was completed in the quarter on 25 November 2024, with a Company announcement that it had entered into a binding agreement to sell its Genetics business area by way of the disposal of Benchmark Genetics Limited and Benchmark Genetics Norway AS and their respective subsidiaries to Starfish Bidco AS, a wholly owned subsidiary of Novo Holdings A/S.  The agreed deal includes initial consideration of £230m, on a debt-free cash-free basis, receivable on completion and additional contingent consideration of up to £30.0m receivable in three years' time based on trading performance of the core salmon subsegment in the period from 1 October 2024 to 30 September 2027.  The deal is subject to customary regulatory clearances and with most of these now received, completion is expected in the next few weeks.  At 30 September 2024, the Genetics business was treated as discontinued operations (see note 8) and the assets and liabilities transferred into held for sale as the sale at the year-end was considered highly probable, and this treatment continues. Included below within liabilities held for sale is £18.6m of borrowings held within Genetics.  The debt-free cash-free terms of the agreed deal prescribe that these facilities will be paid out of the proceeds received at completion.    During the quarter, one of the leased properties held within right of use assets in the Genetics business area was exited resulting in an impairment of £1.7m against the property.   The assets held for sale in Q1 2024 relate to certain property, plant and equipment held withing the Health business area for which a decision was made to sell as it was no longer required by the business.  An impairment charge of £0.4m had been incurred in Q1 2024 to leave the property valued at £0.5m, before eventually being sold in March 2024 for £0.4m.  
Assets held for sale


All figures in £000s
Total assets transferred
Q1 2025 (unaudited)
Total assets transferred
Q1 2024 (unaudited)
Total assets transferred
FY 2024 (audited)
Property, plant and equipment55,33250054,095
Right-of-use assets4,841-7,843
Intangible assets43,743-42,760
Equity-accounted investees2,028-2,304
Biological and agricultural assets46,917-43,107
Inventories475-502
Trade and other receivables11,132-12,641
Total Assets held for sale164,468500163,252
   
Liabilities directly associated with the assets held for sale


All figures in £000s
Total liabilities transferred
Q1 2025 (unaudited)
Total liabilities transferred
Q1 2024 (unaudited)
Total liabilities transferred
FY 2024 (audited)
Trade and other payables(13,454)-(11,754)
Loans and borrowings(18,561)-(22,314)
Corporation tax liability(2,515)-(3,147)
Provisions(608)-(568)
Deferred tax liability(9,042)-(8,914)
Total liabilities directly associated with the assets held for sale(44,180)-(46,697)
11.   Loans and borrowings
Q1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024 (audited)
All figures in £000's
Non-Current
2025 750m NOK Loan notes-57,403-
Bank borrowings-16,349-
Unamortised debt issue costs-(532)-
Lease liabilities2,4016,8122,837
2,40180,0322,837
Current
2025 750m NOK Loan notes52,677-53,125
Bank borrowings20,2509,31516,250
Unamortised debt issue costs(658)(842)(931)
Lease liabilities1,17310,209789
73,44218,68269,233
Total loans and borrowings75,84398,71472,070
  The Group has an unsecured floating rate listed green bond of NOK 750m in issue. The bond which matures in September 2025, has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest payments, and is listed on the Oslo Stock Exchange.   The Group has a secured GBP20m RCF provided by DNB Bank ASA, maturing on 27 June 2025. This facility was extended on the same terms in March 2024 by GBP 7.5m, to a total facility of GBP 27.5m, with the GBP 7.5m extension maturing on 27 March 2025.  On 20 December 2024, the term of the additional £7.5m facility was extended to expire on 27 June 2025 to match the expiry of the original RCF.  The margin on this combined facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the leverage of the Group above the relevant risk-free reference or IBOR rates depending on which currency is drawn.   The Q1 2025 loans and borrowings figure excludes £18.6m (Q1 2024: £nil, FY 2024 £22.3m) which have been classified as held for sale following the decision to sell the Genetics business.     12.   Share capital and additional paid-in share capital
NumberShare CapitalAdditional paid-in
share capital
Allotted, called up and fully paid£000£000
Ordinary shares of 0.1 pence each
Balance at 30 September 2024739,786,14374037,490
Exercise of share options550,100--
Balance at 31 December 2024740,336,24374037,490
  The holders of ordinary shares are entitled to one vote per share at meetings of the company, and to receive dividends from time to time as declared.   During the quarter ended 31 December 2024, the Group issued a total 550,100 ordinary shares of 0.1p each to certain employees of the Group relating to share options, all 550,100 were exercised at 0.1p per share.   13.   Alternative performance measures and other metrics   Management has presented the performance measures EBITDA, Adjusted EBITDA, Adjusted EBITDA before fair value movement in biological assets, Adjusted Operating Profit and Adjusted Profit Before Tax because it monitors performance at a consolidated level using these and believes that these measures are relevant to an understanding of the Group's financial performance.   Adjusted EBITDA which reflects underlying profitability, is earnings before interest, tax, depreciation, amortisation, impairment, and exceptional items and is shown on the Income Statement.   Adjusted EBITDA before fair value movements in biological assets, which is Adjusted EBITDA before the non-cash fair value movements in biological assets arising from their revaluation in line with International Accounting Standards.   Adjusted Operating Profit is operating loss before exceptional items and amortisation and impairment of intangible assets excluding development costs as reconciled below.   Adjusted Profit Before Tax is earnings before tax, amortisation and impairment of intangibles assets excluding development costs, and exceptional items as reconciled below. These measures are not defined performance measures in IFRS. The Group's definition of these measures may not be comparable with similarly titled performance measures and disclosures by other entities.   Reconciliation of adjusted operating profit/(loss) to operating loss (continuing)
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Revenue17,72225,31390,365
Cost of sales(10,146)(12,563)(46,418)
Gross profit7,57612,75043,947
Research and development costs(567)(687)(2,443)
Other operating costs(7,257)(8,568)(29,582)
Depreciation and impairment(840)(5,093)(10,949)
Amortisation and impairment of capitalised development costs(27)(454)(17,569)
Adjusted operating loss(1,115)(2,052)(16,596)
Exceptional including acquisition related items(1,574)(94)(5,581)
Amortisation and impairment of intangible assets excluding development costs(3,354)(3,410)(13,322)
Operating loss(6,043)(5,556)(35,499)
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   Reconciliation of adjusted loss before taxation to adjusted operating loss (continuing)
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Loss before taxation(7,067)(9,089)(45,925)
Exceptional - restructuring, acquisition and disposal related items1,574945,581
Amortisation and impairment of intangible assets excluding development costs3,3543,41013,322
Adjusted loss before tax(2,139)(5,585)(27,022)
*Q1 2024 numbers were restated to reflect the results of the Genetics business being classified as discontinued operations in FY24 in line with IFRS5 following the decision to sell the business area (see note 8).   13.  Alternative performance measures and other metrics (continued)   Other Metrics
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
Restated*
(unaudited)
FY 2024
(audited)
Total R&D Investment
Research and development costs
- Continuing operations5676872,443
- Discontinued operations8718303,276
Internal capitalised development costs-62149
Total R&D investment1,4381,5795,868
  Liquidity   A key financial covenant is a minimum liquidity of £10m, defined as cash plus undrawn facilities.  
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024
(audited)
Cash and cash equivalents13,80824,16423,088
Undrawn bank facility7,25012,25011,250
Total liquidity21,05836,41434,338
  The undrawn bank facility relates to the RCF facility which was increased from £20m to £27.5m in FY 2024.  At 31 December 2024, £20.25m of the RCF was drawn (Q1 2024: £7.75m, FY 2024: £16.25m), leaving £7.25m undrawn (Q1 2024: £12.25, FY 2024: £11.25m).   14.   Net debt Net debt is cash and cash equivalents less loans and borrowings.
All figures in £000'sQ1 2025
(unaudited)
Q1 2024
(unaudited)
FY 2024 (audited)
Cash and cash equivalents13,80824,16423,088
Loans and borrowings (excluding lease liabilities) - current(72,269)(8,473)(68,444)
Loans and borrowings (excluding lease liabilities) - non-current-(73,220)-
Net debt excluding lease liabilities(58,461)(57,529)(45,356)
Lease liabilities - current(1,173)(10,209)(789)
Lease liabilities - non-current(2,401)(6,812)(2,837)
Net debt(62,035)(74,550)(48,982)
  The above figures exclude loans and borrowings of £18,561,000 at 31 December 2024 (31 December 2023: £nil; 30 September 2024: £22,314,000) relating to the Genetics business and included in liabilities held for sale in note 10.     This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END     QRFPPURPPUPAGMM

Recent news on Benchmark Holdings

See all news